Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial
暂无分享,去创建一个
J. Cayuela | A. Vekhoff | P. Cony-Makhoul | C. Preudhomme | E. Deconinck | A. Delmer | P. Rousselot | K. Ghomari | F. Mahon | L. Fouillard | M. Berger | L. Lhermitte | F. Guilhot | F. Nicolini | M. Delord | L. Roy | J. Chomel | E. Jourdan | V. Coiteux | E. Gyan | C. Berthou | F. Maloisel | P. Lenain | S. Glaisner | D. Caillot | I. Plantier | B. Joly | J. Kiladjian | G. Étienne | Y. Arkam | A. Charbonnier | H. Maisonneuve | J. Guilhot | D. Réa | M. Alexis | M. Mercier | J. Chapiro | A. Santagostino | C. Bulabois | V. Dubruille | L. Legros | M. Gardembas | A. Guerci-Bresler | N. Cambier | J. Miclea | H. Johnson-Ansah | H. Zerazhi | D. Lebon | V. Dorvaux | I. Vaida | A. Penot | Charbonnier Aude | B. Pollet | Marc Muller | F. Rigal-huguet | Martine Escoffre Barbe | Jean-Claude Chomel | Francois Francoise Joëlle Agnès-Paule Delphine Valérie Mart Guilhot Rigal-Huguet Guilhot Guerci-Bres